Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 48.12 Billion KRW | -8.0% |
| 2022 | 52.31 Billion KRW | 402.06% |
| 2021 | 10.41 Billion KRW | 3.78% |
| 2020 | 10.03 Billion KRW | 14.63% |
| 2019 | 8.75 Billion KRW | 4.28% |
| 2018 | 8.39 Billion KRW | -4.95% |
| 2017 | 8.83 Billion KRW | 8.9% |
| 2016 | 8.11 Billion KRW | 25.02% |
| 2015 | 6.49 Billion KRW | -2.7% |
| 2014 | 6.67 Billion KRW | 16.81% |
| 2013 | 5.71 Billion KRW | -25.31% |
| 2012 | 7.64 Billion KRW | 36.4% |
| 2011 | 5.6 Billion KRW | -22.95% |
| 2010 | 7.27 Billion KRW | -3.32% |
| 2009 | 7.52 Billion KRW | -1.48% |
| 2008 | 7.63 Billion KRW | 62.24% |
| 2007 | 4.7 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 54.93 Billion KRW | 6.82% |
| 2024 Q1 | 51.42 Billion KRW | 6.86% |
| 2023 Q3 | 57.67 Billion KRW | 1.03% |
| 2023 Q2 | 57.09 Billion KRW | -7.28% |
| 2023 FY | 48.12 Billion KRW | -8.0% |
| 2023 Q1 | 61.57 Billion KRW | 17.71% |
| 2023 Q4 | 48.12 Billion KRW | -16.56% |
| 2022 Q1 | 9.66 Billion KRW | -7.22% |
| 2022 FY | 52.31 Billion KRW | 402.06% |
| 2022 Q4 | 52.31 Billion KRW | 408.56% |
| 2022 Q3 | 10.28 Billion KRW | -3.67% |
| 2022 Q2 | 10.67 Billion KRW | 10.45% |
| 2021 FY | 10.41 Billion KRW | 3.78% |
| 2021 Q4 | 10.41 Billion KRW | 5.73% |
| 2021 Q1 | 11.32 Billion KRW | 12.84% |
| 2021 Q2 | 10.13 Billion KRW | -10.55% |
| 2021 Q3 | 9.85 Billion KRW | -2.74% |
| 2020 FY | 10.03 Billion KRW | 14.63% |
| 2020 Q4 | 10.03 Billion KRW | -6.2% |
| 2020 Q3 | 10.7 Billion KRW | 2.12% |
| 2020 Q1 | 9.68 Billion KRW | 10.62% |
| 2020 Q2 | 10.48 Billion KRW | 8.17% |
| 2019 Q2 | 8.93 Billion KRW | 4.97% |
| 2019 Q4 | 8.75 Billion KRW | -2.87% |
| 2019 FY | 8.75 Billion KRW | 4.28% |
| 2019 Q1 | 8.51 Billion KRW | 1.4% |
| 2019 Q3 | 9.01 Billion KRW | 0.87% |
| 2018 Q2 | 9.09 Billion KRW | 1.69% |
| 2018 Q3 | 8.98 Billion KRW | -1.26% |
| 2018 FY | 8.39 Billion KRW | -4.95% |
| 2018 Q4 | 8.39 Billion KRW | -6.48% |
| 2018 Q1 | 8.94 Billion KRW | 1.22% |
| 2017 Q4 | 8.83 Billion KRW | -5.36% |
| 2017 FY | 8.83 Billion KRW | 8.9% |
| 2017 Q3 | 9.33 Billion KRW | 7.91% |
| 2017 Q2 | 8.65 Billion KRW | 3.44% |
| 2017 Q1 | 8.36 Billion KRW | 3.08% |
| 2016 FY | 8.11 Billion KRW | 25.02% |
| 2016 Q2 | 7.16 Billion KRW | 17.97% |
| 2016 Q3 | 8.19 Billion KRW | 14.37% |
| 2016 Q4 | 8.11 Billion KRW | -1.02% |
| 2016 Q1 | 6.07 Billion KRW | -6.39% |
| 2015 Q3 | 6.94 Billion KRW | 11.42% |
| 2015 Q4 | 6.49 Billion KRW | -6.57% |
| 2015 Q1 | 6.56 Billion KRW | -1.65% |
| 2015 Q2 | 6.23 Billion KRW | -4.97% |
| 2015 FY | 6.49 Billion KRW | -2.7% |
| 2014 Q2 | 6.03 Billion KRW | 10.7% |
| 2014 Q1 | 5.44 Billion KRW | -4.6% |
| 2014 FY | 6.67 Billion KRW | 16.81% |
| 2014 Q4 | 6.67 Billion KRW | -6.31% |
| 2014 Q3 | 7.11 Billion KRW | 18.05% |
| 2013 Q4 | 5.71 Billion KRW | -12.66% |
| 2013 FY | 5.71 Billion KRW | -25.31% |
| 2013 Q3 | 6.53 Billion KRW | -24.91% |
| 2013 Q2 | 8.7 Billion KRW | 13.11% |
| 2013 Q1 | 7.69 Billion KRW | 0.69% |
| 2012 FY | 7.64 Billion KRW | 36.4% |
| 2012 Q4 | 7.64 Billion KRW | 0.0% |
| 2012 Q1 | 3.94 Billion KRW | 0.0% |
| 2011 Q1 | 5.47 Billion KRW | 0.0% |
| 2011 FY | 5.6 Billion KRW | -22.95% |
| 2011 Q3 | 5.24 Billion KRW | 14.94% |
| 2011 Q2 | 4.55 Billion KRW | -16.68% |
| 2010 Q1 | 5.09 Billion KRW | 22.16% |
| 2010 FY | 7.27 Billion KRW | -3.32% |
| 2010 Q2 | 5.11 Billion KRW | 0.48% |
| 2009 Q4 | 4.16 Billion KRW | 0.0% |
| 2009 FY | 7.52 Billion KRW | -1.48% |
| 2009 Q2 | 5.34 Billion KRW | 0.75% |
| 2009 Q1 | 5.3 Billion KRW | -9.29% |
| 2008 FY | 7.63 Billion KRW | 62.24% |
| 2008 Q2 | 5.32 Billion KRW | 4.65% |
| 2008 Q1 | 5.08 Billion KRW | -0.46% |
| 2008 Q4 | 5.84 Billion KRW | 0.0% |
| 2007 Q1 | 4.99 Billion KRW | 0.0% |
| 2007 Q2 | 4.37 Billion KRW | -12.4% |
| 2007 FY | 4.7 Billion KRW | 0.0% |
| 2007 Q4 | 5.1 Billion KRW | 8.49% |
| 2007 Q3 | 4.7 Billion KRW | 7.55% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -9.005% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 59.162% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 47.208% |
| HANDOK Inc. | 94.46 Billion KRW | 49.052% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -126.559% |
| Yuhan Corporation | 284.75 Billion KRW | 83.099% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 58.622% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -196.015% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 83.336% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -48.616% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 22.028% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -147.102% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -58.943% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 0.453% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -9.005% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -54.056% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -36.819% |
| JW Holdings Corporation | 147.58 Billion KRW | 67.391% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 43.127% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 81.591% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 54.635% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 10.747% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -78.266% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -48.035% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 56.155% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -9.005% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 74.487% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 80.075% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 54.635% |
| Yuhan Corporation | 284.75 Billion KRW | 83.099% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 61.584% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 22.357% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 81.478% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 54.635% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 39.54% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 2.063% |
| CKD Bio Corp. | 69.08 Billion KRW | 30.332% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 54.198% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 31.923% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 10.969% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 10.747% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 75.289% |
| Boryung Corporation | 189.8 Billion KRW | 74.643% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 15.315% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 22.028% |
| JW Lifescience Corporation | 23.39 Billion KRW | -105.688% |